Blog

On October 3, 2017, the U.S. Food and Drug Administration (FDA) issued a statement on the risk of hemorrhagic occlusive retinal vasculitis (HORV) following injections directly into the eye of a compounded triamcinolone, moxifloxacin, and vancomycin (TMV) formulation. The FDA’s statement follows a recent report of a patient who was diagnosed with HORV after being… Read more »